Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662812 · ClinicalTrials.gov registry record
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 1,665
- Enrollment target
NCT06662812 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 1,665 participants.
The verdict
NCT06662812 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 1,665 participants
- Enrollment target
Study Summary
This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,665 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662812
The ClinicalTrials.gov registry entry for NCT06662812 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06662812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06662812 about?
NCT06662812 is a clinical study titled "Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry". This was a retrospective observational cohort study. This study was a secondary analysis of individuals with sickle cell disease (SCD) enrolled in the GRNDaD registry.
What is the current status of trial NCT06662812?
This trial is currently completed. The enrollment target is 1,665 participants. The study started on 2021-10-06. Estimated completion is 2023-12-01.
Who is sponsoring clinical trial NCT06662812?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.